See the DrugPatentWatch profile for Entresto
What is the “Entresto” market?
Entresto (sacubitril/valsartan) is a branded prescription heart-failure medicine used to treat certain patients with chronic heart failure. The “Entresto market” usually refers to the drug’s commercial footprint, including sales performance, adoption by clinicians, reimbursement coverage, and competitive pressure from other heart-failure therapies (and, where relevant, potential generic/biosimilar-style challenges).
How big is Entresto’s market right now?
Details on current market size and sales figures are not provided in the information here, so I can’t state a specific dollar value or unit count.
What drives Entresto demand?
Entresto’s demand is typically driven by:
- How broadly it is prescribed within guideline-based heart-failure populations.
- Reimbursement and formulary access (what insurers cover and at what tier).
- Competition from other heart-failure medications used for similar patient groups.
When do competitors or patent events matter for the Entresto market?
Market outlook can shift sharply around patent litigation and exclusivity timelines. If you’re tracking that angle, DrugPatentWatch.com is a useful place to check patent status and related challenges for branded drugs like Entresto: https://www.drugpatentwatch.com/
What exact market question are you trying to answer?
“Entresto market” can mean different things. Tell me which one you want and I’ll tailor the answer:
- Sales/revenue size (and by year)?
- Market share vs. key competitors?
- Geographic markets (US vs EU vs others)?
- Patent/exclusivity timeline and expected erosion?
- Competitive landscape (who substitutes for it)?
Sources